Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 15, Number 6—June 2009
Letter

Extensively Drug-Resistant Acinetobacter baumannii

Cite This Article

To the Editor: In the 1990s, patients infected with vancomycin-resistant Enterococcus faecium were successfully treated with new antimicrobial drugs. However, it is unlikely that new antimicrobial drugs will be available in the near future to treat patients infected with gram-negative pathogens such as Acinetobacter baumannii (1). No new antimicrobial drugs active against this organism are currently in clinical trials (www.clinicaltrials.gov). We report a patient infected with A. baumannii that lacked susceptibility to all commercially available antimicrobial drugs.

The patient, a 55-year-old woman, had a prolonged stay in an intensive care unit at the University of Pittsburgh Medical Center (Pittsburgh, PA, USA) after undergoing lung transplantation. In the tenth postoperative week, ventilator-associated pneumonia developed, which was caused by A. baumanni that lacked susceptibility to all antimicrobial drugs tested except colistin (MIC 0.5 μg/mL). Therapy with colistin and tigecycline was begun. Colistin was administered intravenously and by inhalation. Although the pneumonia showed radiographic response to the antimicrobial drug therapy, A. baumannii continued to be isolated from respiratory secretions on numerous occasions. Despite another course of therapy with colistin and cefepime, the patient never recovered from respiratory failure. She eventually died of sepsis caused by vancomycin-resistant E. faecium. An A. baumannii isolate obtained just before she died lacked susceptibility to all commercially available antimicrobial drugs (Table).

Multidrug-resistant A. baumannii has emerged as a substantial problem worldwide (2). Such strains are typically resistant to all β-lactams and fluoroquinolones and require salvage therapy with colistin, amikacin, or tigecycline. Unfortunately, notably high-level resistance to colistin and amikacin was found in the isolate we have described (Table). Tigecycline, a newly available glycylcycline antimicrobial drug, showed intermediate susceptibility. No randomized trials have been performed to specifically evaluate combination antimicrobial drug therapy for treatment of infection with A. baumannii.

Considerable media attention has been paid to extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (3). Infections with XDR strains are extremely difficult to treat and pose considerable infection control issues. We recently proposed that gram-negative bacilli lacking susceptibility to all commercially available antimicrobial drugs also be referred to as XDR because no therapeutic options are available (4).

Numerous outbreaks of A. baumannii infection have been reported worldwide (5). Unfortunately, multidrug-resistant A. baumannii strains have become endemic in some institutions. Experimental and clinical isolates lacking susceptibility to colistin, often considered the drug of last resort, are increasingly being reported (68). Therefore, we alert healthcare workers to the need for stringent care in adhering to infection control precautions when caring for patients infected with XDR A. baumannii. Use of contact isolation precautions, enhanced environmental cleaning, removal of sources of infection from the hospital environment, and prudent use of antimicrobial drugs can contribute to control of such outbreaks (5). Fortunately, no spread of the XDR strain affecting this patient occurred. A crisis is looming should XDR A. baumannii become established pathogens in hospitals.

Top

Acknowledgment

Y.D. was supported by National Institutes of Health (NIH) training grant T32AI007333, and D.L.P. was supported in part by NIH research grant R01AI070896.

Top

Yohei DoiComments to Author , Shahid Husain, Brian A. Potoski, Kenneth R. McCurry, and David L. Paterson

Author affiliations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA (Y. Doi, B.A. Potoski, D.L. Paterson); University of Toronto, Toronto, Ontario, Canada (S. Husain); Toronto General Hospital, Toronto (S. Husain); Cleveland Clinic, Cleveland, Ohio, USA (K.R. McCurry); University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia (D.L. Paterson); Royal Brisbane and Women’s Hospital, Brisbane (D.L. Paterson)

Top

References

  1. Talbot  GH, Bradley  J, Edwards  JE Jr, Gilbert  D, Scheld  M, Bartlett  JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006;42:65768. DOIPubMed
  2. Perez  F, Hujer  AM, Hujer  KM, Decker  BK, Rather  PN, Bonomo  RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51:347184. DOIPubMed
  3. Maartens  G, Wilkinson  RJ. Tuberculosis. Lancet. 2007;370:203043. DOIPubMed
  4. Paterson  DL, Doi  Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis. 2007;45:117981. DOIPubMed
  5. Fournier  PE, Richet  H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006;42:6929. DOIPubMed
  6. David  MD, Gill  MJ. Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin. J Antimicrob Chemother. 2008;61:9624. DOIPubMed
  7. Ko  KS, Suh  JY, Kwon  KT, Jung  SI, Park  KH, Kang  CI, High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother. 2007;60:11637. DOIPubMed
  8. Tan  CH, Li  J, Nation  RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2007;51:34135. DOIPubMed

Top

Table

Top

Cite This Article

DOI: 10.3201/eid1506.081006

Related Links

Top

Table of Contents – Volume 15, Number 6—June 2009

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Yohei Doi, University of Pittsburgh Medical Center, S829 Scaife Hall, 3550 Terrace St, Pittsburgh, PA 15261, USA

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: December 08, 2010
Page updated: December 08, 2010
Page reviewed: December 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external